NYSE:CPHI China Pharma (CPHI) Stock Price, News & Analysis $1.93 +0.02 (+1.05%) As of 10:43 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesSEC FilingsTrendsBuy This Stock About China Pharma Stock (NYSE:CPHI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get China Pharma alerts:Sign Up Key Stats Today's Range$1.90▼$1.9750-Day Range$1.50▼$29.4952-Week Range$1.20▼$4.10Volume1,985 shsAverage Volume65,431 shsMarket Capitalization$6.30 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewChina Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.Read More… Receive CPHI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for China Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address CPHI Stock News HeadlinesChina Pharma (NYSE:CPHI) Research Coverage Started at StockNews.comApril 26, 2025 | americanbankingnews.comAmCham China President Says Pharma Companies Have Reported Tariff Exemptions on China ImportsApril 25, 2025 | msn.comWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.May 5, 2025 | Altimetry (Ad)China Pharma announces 1-for-10 reverse stock splitApril 5, 2025 | markets.businessinsider.comThe US relies on China for key medicines. They won’t be spared from tariffsFebruary 9, 2025 | msn.comChina Pharma Holdings, Inc.January 26, 2025 | seekingalpha.comChina Pharma Holdings, Inc. Completes Full Redemptions Under Convertible Note Agreement with StreetervilleDecember 18, 2024 | prnewswire.comChina Pharma Announces the Entry of "At-The-Market" Equity OfferingDecember 13, 2024 | prnewswire.comSee More Headlines CPHI Stock Analysis - Frequently Asked Questions How have CPHI shares performed this year? China Pharma's stock was trading at $23.00 at the start of the year. Since then, CPHI shares have decreased by 91.6% and is now trading at $1.93. View the best growth stocks for 2025 here. How were China Pharma's earnings last quarter? China Pharma Holdings, Inc. (NYSE:CPHI) released its earnings results on Wednesday, August, 15th. The company reported ($100.00) earnings per share for the quarter. The company had revenue of $3.17 million for the quarter. China Pharma had a negative net margin of 85.56% and a negative trailing twelve-month return on equity of 63.93%. When did China Pharma's stock split? China Pharma shares reverse split on Tuesday, April 15th 2025. The 1-10 reverse split was announced on Friday, April 4th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 14th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of China Pharma? Shares of CPHI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of China Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that China Pharma investors own include iBio (IBIO), Biocept (BIOC), Micron Technology (MU), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), Tonix Pharmaceuticals (TNXP) and Bionano Genomics (BNGO). Company Calendar Last Earnings8/15/2018Today5/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:CPHI CIK1106644 Webwww.chinapharmaholdings.com Phone8689866811730Fax86-898-6681-9024Employees250Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,080,000.00 Net Margins-85.56% Pretax Margin-85.56% Return on Equity-63.93% Return on Assets-31.42% Debt Debt-to-Equity Ratio0.22 Current Ratio0.79 Quick Ratio0.26 Sales & Book Value Annual Sales$4.53 million Price / Sales1.38 Cash FlowN/A Price / Cash FlowN/A Book Value$0.70 per share Price / Book2.73Miscellaneous Outstanding Shares3,262,000Free Float15,918,000Market Cap$6.23 million OptionableNot Optionable Beta0.77 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NYSE:CPHI) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding China Pharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share China Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.